ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.498,38
0,32%
S&P 500
5.187,10
-0,01%
Dow Jones
39.040,45
0,40%
Euro vs US Dollar
1,07424
-0,07%
Bitcoin
62.683,91
0,56%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) News

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NYSE:TEVA
DatumZeitQuelleÜberschriftSymbolFirma
08/05/202413h00Business WireTeva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial OutlookNYSE:TEVATeva Pharmaceutical Industries Ltd
08/05/202412h30Business WireTeva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with SchizophreniaNYSE:TEVATeva Pharmaceutical Industries Ltd
03/05/202400h30Business WireTeva to Present at the 2024 Bank of America Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
02/05/202414h30Business WireTeva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious TargetsNYSE:TEVATeva Pharmaceutical Industries Ltd
30/04/202410h00Business WireU.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)NYSE:TEVATeva Pharmaceutical Industries Ltd
30/04/202410h00GlobeNewswire Inc.U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)NYSE:TEVATeva Pharmaceutical Industries Ltd
16/04/202423h43Business WireAlvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)NYSE:TEVATeva Pharmaceutical Industries Ltd
16/04/202423h30GlobeNewswire Inc.Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)NYSE:TEVATeva Pharmaceutical Industries Ltd
16/04/202414h00Business WireTeva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) TabletsNYSE:TEVATeva Pharmaceutical Industries Ltd
11/04/202414h30Business WireTeva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in ChinaNYSE:TEVATeva Pharmaceutical Industries Ltd
09/04/202422h30Business WireTeva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024NYSE:TEVATeva Pharmaceutical Industries Ltd
06/04/202419h00Business WireNew Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024NYSE:TEVATeva Pharmaceutical Industries Ltd
04/04/202414h30Business WireTeva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar CandidateNYSE:TEVATeva Pharmaceutical Industries Ltd
01/04/202414h30Business WireClinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding AgreementNYSE:TEVATeva Pharmaceutical Industries Ltd
07/03/202422h27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
07/03/202422h24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
07/03/202422h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
07/03/202422h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
07/03/202422h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
07/03/202422h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
05/03/202422h46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
05/03/202422h43Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
05/03/202422h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
05/03/202422h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
05/03/202422h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
05/03/202422h27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
05/03/202422h25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
05/03/202422h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
05/03/202422h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
05/03/202422h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Kürzlich von Ihnen besucht

TG
DBK
Deutsche Bank
AMEX
SPY
SPDR S&P 500
NASDAQ
NVDA
NVIDIA
USOTC
RHHBY
Roche (QX)
DBI
MDAX
MDAX
NYSE
DIS
Walt Disney
USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
MSFT
Microsoft
NYSE
XOM
Exxon Mobil
PM
XAUUSD
Gold vs US Dollar
USOTC
BASFY
BASF (QX)
FX
EURJPY
Euro vs Yen
TG
DTE
Deutsche Telekom
TG
TUI1
Tui
NASDAQ
TSLA
Tesla
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten